Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (8045)	3/19/2003 9:08:33 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Ian, I personally don't think the ISIS failure makes GNTA any more likely to fail. The other challenge to antisense is the newer RNAi technology. The best play here is likely the "new" RZYM - I actually bought a very little a week or two back at around $0.30 when they announced their reverse split (often a good time to buy a stock if you know they will survive). Their recent pop two days ago was likely a transient event, based on GERN's equally unsustainable pop. Peter